Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23768195 | 0.79 | KDM4E (0.52) | KDM4EPKMCNR2RAB9AALDH1A1 | |
| SCHEMBL1399272 | 0.77 | MAPT (0.68) | RAB9AALDH1A1MAPTSMN1; SMN2GAA | |
| SCHEMBL19913061 | 0.76 | CNR2 (0.46) | KDM4ECNR2RAB9AALDH1A1MAPT | |
| SCHEMBL16840723 | 0.76 | KDM4E (0.56) | KDM4EPKMCNR2RAB9AALDH1A1 | |
| SCHEMBL17857301 | 0.75 | GAA (0.44) | KDM4ECNR2RAB9AALDH1A1MAPT | |
| SCHEMBL21119857 | 0.74 | GAA (0.48) | KDM4ECNR2ALDH1A1MAPTGAA | |
| SCHEMBL5754979 | 0.73 | ALDH1A1 (0.61) | KDM4EPKMCNR2RAB9AALDH1A1 | |
| SCHEMBL10970673 | 0.73 | KDM4E (0.56) | KDM4EPKMCNR2RAB9AALDH1A1 | |
| Sulfuric Acid SCHEMBL11167741 | 0.72 | KDM4E (0.59) | KDM4EPKMCNR2RAB9AALDH1A1 | |
| Hydrochloric Acid SCHEMBL11192350 | 0.72 | KDM4E (0.55) | KDM4EPKMCNR2RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3233839-B1 | HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KBETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-09-25 | — | — | EP | disclosed |
| EP-3233862-B1 | IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KBETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-07-03 | — | — | EP | disclosed |
| US-10202387-B2 | Heterocyclyl linked imidazopyridazine derivatives as PI3KB inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2019-02-12 | — | — | US | disclosed |
| US-20180057496-A1 | HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS | JANSSEN-CILAG (FR) | 2018-03-01 | — | — | US | disclosed |
| WO-2016097359-A1 | HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KBETA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016097347-A1 | IMIDAZOPYRIDAZINE DERIVATIVES AS ΡΙ3Κβ INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202387-B2 | Heterocyclyl linked imidazopyridazine derivatives as PI3KB inhibitors | PIK3CB, PIK3CD, PIK3CA | KDM4E 1958/4885PKM 1341/4885CNR2 1333/4885 |
| US-20180057496-A1 | HETEROCYCLYL LINKED IMIDAZOPYRIDAZINE DERIVATIVES AS PI3KB INHIBITORS | PIK3CB, PIK3CD, PIK3CA | KDM4E 1958/4885PKM 1341/4885CNR2 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.